We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-0.73%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$841M
AUM Growth
-$257M
(-23%)
Cap. Flow
+$27.7M
Cap. Flow
% of AUM
3.29%
Top 10 Holdings %
Top 10 Hldgs %
71.13%
Holding
232
New
70
Increased
34
Reduced
47
Closed
75
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$56.8M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$12.1M |
| 3 |
Cogent Biosciences
COGT
|
+$9.38M |
| 4 |
Incyte
INCY
|
+$7.38M |
| 5 |
Nektar Therapeutics
NKTR
|
+$3.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$58.4M |
| 2 |
ESPR
Esperion Therapeutics
ESPR
|
+$9.06M |
| 3 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$6.4M |
| 4 |
MannKind Corp
MNKD
|
+$3.35M |
| 5 |
AbbVie
ABBV
|
+$3.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 83.05% |
| 2 | Healthcare | 16.08% |
| 3 | Consumer Staples | 0.43% |
| 4 | Consumer Discretionary | 0.12% |
| 5 | Materials | 0.09% |
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q1 2018 Portfolio in Review
As of Q1 2018, Sabby Management held 232 positions worth $841M, down 23% from $1.1B the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Sabby Management deployed $27.7M of net new capital in Q1 2018, opening 70 new positions and adding to 34 existing holdings. Its largest new stake was Biogen: 182,898 shares worth $50.1M.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 87% a quarter earlier, followed by Healthcare and Consumer Staples.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $58.4M trimmed.
- Sabby Management's largest Q1 2018 buy was Biogen: 182,898 shares worth $50.1M.
- Sabby Management added most to Nektar Therapeutics in Q1 2018, an estimated $3.34M increase.
- Sabby Management's biggest Q1 2018 reduction was Bristol-Myers Squibb, cutting an estimated $58.4M.
- Sabby Management fully exited Spark Therapeutics, Inc. Common Stock in Q1 2018, selling an estimated $6.4M.
- Sabby Management's ten largest holdings make up 71% of its $841M portfolio in Q1 2018.
- Sabby Management opened 70 new positions and closed 75 in Q1 2018.
- Sabby Management's portfolio value fell 23% quarter-over-quarter to $841M.
Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.